explore -WSS

explore

author：leisure time 2025-10-02 17:27:25 - browse：79886

translucent 3D DNA helix with blue and purple background — Adobe

Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

“We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

focus

WSS

The FDA must approve intranasal treatments for anaphylaxis

Scientific mystery highlights the blind spots in genomics databases

Chronically ill young patients struggle to find fertility info

The biotech scorecard for Q1: 17 stock

Mass General Brigham physicians react to latest merger step

Florida Supreme Court upholds state's abortion ban

explore

explore

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

U.K. sequencing study surfaces new findings about tumor DNA

Jerome Adams on the need for new antivirals for Covid

Hundreds died while taking an arthritis drug, but nobody alerted patients

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Walensky prepares to leave CDC — and Congress — behind

Oral obesity drug from Viking Therapeutics hits key early target

entertainment

Multiple sclerosis has subtypes with different best treatments: study

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

The FDA must approve intranasal treatments for anaphylaxis

JPM: CVS says Medicare Advantage patients are impacting profits

Study: Black kids more likely to die after surgery than white kids

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

focus

hotspot

focus

leisure time